Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enliven Therapeutics (ELVN) Income from Continuing Operations (2019 - 2026)

Enliven Therapeutics has reported Income from Continuing Operations over the past 8 years, most recently at 23627000.0 for Q1 2026.

  • Quarterly results put Income from Continuing Operations at 23627000.0 for Q1 2026, up 17.09% from a year ago — trailing twelve months through Mar 2026 was 891000.0 (up 99.07% YoY), and the annual figure for FY2025 was 5761000.0, up 93.59%.
  • Income from Continuing Operations reached 23627000.0 in Q1 2026 per ELVN's latest filing, down from 68217000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 68217000.0 in Q4 2025 and bottomed at 28497000.0 in Q1 2025.
  • Median Income from Continuing Operations over the past 5 years was 20148000.0 (2025), compared with a mean of 13441588.24.
  • The largest annual shift saw Income from Continuing Operations crashed 102.73% in 2023 before it skyrocketed 394.29% in 2025.
  • Over 5 years, Income from Continuing Operations stood at 9550000.0 in 2022, then plummeted by 102.73% to 19361000.0 in 2023, then decreased by 19.73% to 23180000.0 in 2024, then surged by 394.29% to 68217000.0 in 2025, then plummeted by 134.64% to 23627000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for ELVN at 23627000.0 in Q1 2026, 68217000.0 in Q4 2025, and 20148000.0 in Q3 2025.